* Remains in discussions with FDA regarding its supplemental
new drug application, or SNDA, for migraine
The post BRIEF-Supernus reiterates guidance appeared first on NASDAQ.
Forex – financial instrument.Forex news
* Remains in discussions with FDA regarding its supplemental
new drug application, or SNDA, for migraine
The post BRIEF-Supernus reiterates guidance appeared first on NASDAQ.